机译:肝脏移植患者中浸毒和地塞米松治疗肝淀粉样蛋白轻链淀粉样蛋白病
Department of Gastroenterological and Transplant SurgeryHiroshima UniversityHiroshima Japan;
Department of Gastroenterological and Transplant SurgeryHiroshima UniversityHiroshima Japan;
Department of Gastroenterological and Transplant SurgeryHiroshima UniversityHiroshima Japan;
Department of Gastroenterological and Transplant SurgeryHiroshima UniversityHiroshima Japan;
Department of Gastroenterological and Transplant SurgeryHiroshima UniversityHiroshima Japan;
Department of Gastroenterological and Transplant SurgeryHiroshima UniversityHiroshima Japan;
Department of Gastroenterological and Transplant SurgeryHiroshima UniversityHiroshima Japan;
Department of Hematology and OncologyHiroshima UniversityHiroshima Japan;
Department of Hematology and OncologyHiroshima UniversityHiroshima Japan;
Department of PathologyHiroshima UniversityHiroshima Japan;
Department of Medicine and Molecular ScienceHiroshima UniversityHiroshima Japan;
Department of Gastroenterological and Transplant SurgeryHiroshima UniversityHiroshima Japan;
adjuvant chemotherapy; amyloid light‐chain amyloidosis; bortezomib; cirrhosis; dexamethasone; liver transplant;
机译:肝脏移植患者中浸毒和地塞米松治疗肝淀粉样蛋白轻链淀粉样蛋白病
机译:肝移植是系统性轻链淀粉样变性病伴有肝功能亢进的潜在治疗选择:一例病例报告和文献分析
机译:肝移植是全身轻链淀粉样蛋白病患者的潜在治疗选择,患有肝脏受累的患者:文献的案例报告和分析审查
机译:来自淀粉样蛋白轻链淀粉样蛋白症的患者淀粉样蛋白轻链蛋白的氧化后翻译修饰
机译:患有原发性淀粉样变性病患者的产生淀粉样蛋白的免疫球蛋白轻链的质谱表征。
机译:硼替佐米来那度胺和地塞米松对轻链淀粉样变性的主要治疗
机译:肝移植是系统轻链淀粉样蛋白患者占主导地位肝脏受累的潜在治疗选择:对文献的案例报告和分析审查